CA2729054C - Antagonists of actriib and uses for increasing red blood cell levels - Google Patents

Antagonists of actriib and uses for increasing red blood cell levels Download PDF

Info

Publication number
CA2729054C
CA2729054C CA2729054A CA2729054A CA2729054C CA 2729054 C CA2729054 C CA 2729054C CA 2729054 A CA2729054 A CA 2729054A CA 2729054 A CA2729054 A CA 2729054A CA 2729054 C CA2729054 C CA 2729054C
Authority
CA
Canada
Prior art keywords
polypeptide
amino acid
acid sequence
seq
activin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2729054A
Other languages
English (en)
French (fr)
Other versions
CA2729054A1 (en
Inventor
Matthew L. Sherman
Jasbir Seehra
Niels Borgstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Priority to CA3049354A priority Critical patent/CA3049354A1/en
Publication of CA2729054A1 publication Critical patent/CA2729054A1/en
Application granted granted Critical
Publication of CA2729054C publication Critical patent/CA2729054C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2729054A 2008-06-26 2009-06-26 Antagonists of actriib and uses for increasing red blood cell levels Active CA2729054C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3049354A CA3049354A1 (en) 2008-06-26 2009-06-26 Antagonists of actriib and uses for increasing red blood cell levels

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13336808P 2008-06-26 2008-06-26
US61/133,368 2008-06-26
PCT/US2009/003808 WO2009158015A2 (en) 2008-06-26 2009-06-26 Antagonists of actriib and uses for increasing red blood cell levels

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3049354A Division CA3049354A1 (en) 2008-06-26 2009-06-26 Antagonists of actriib and uses for increasing red blood cell levels

Publications (2)

Publication Number Publication Date
CA2729054A1 CA2729054A1 (en) 2009-12-30
CA2729054C true CA2729054C (en) 2019-09-03

Family

ID=41445146

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2729054A Active CA2729054C (en) 2008-06-26 2009-06-26 Antagonists of actriib and uses for increasing red blood cell levels
CA3049354A Abandoned CA3049354A1 (en) 2008-06-26 2009-06-26 Antagonists of actriib and uses for increasing red blood cell levels
CA2729098A Active CA2729098C (en) 2008-06-26 2009-06-26 Antagonists of activin-actriia and uses for increasing red blood cell levels

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA3049354A Abandoned CA3049354A1 (en) 2008-06-26 2009-06-26 Antagonists of actriib and uses for increasing red blood cell levels
CA2729098A Active CA2729098C (en) 2008-06-26 2009-06-26 Antagonists of activin-actriia and uses for increasing red blood cell levels

Country Status (10)

Country Link
EP (4) EP2303917B1 (enExample)
JP (8) JP5773868B2 (enExample)
KR (4) KR102024444B1 (enExample)
CN (2) CN102131515B (enExample)
AU (4) AU2009262968A1 (enExample)
CA (3) CA2729054C (enExample)
DK (1) DK2318028T3 (enExample)
ES (2) ES2791699T3 (enExample)
NZ (2) NZ602471A (enExample)
WO (2) WO2009158015A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005266875B2 (en) 2004-07-23 2012-07-26 Acceleron Pharma Inc. ActRII receptor polypeptides, methods and compositions
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CN105001320A (zh) 2005-11-23 2015-10-28 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CN101835485B (zh) 2007-02-01 2016-10-26 阿塞勒隆制药公司 活化素-actriia拮抗剂及在治疗或预防乳腺癌中的用途
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
JP5574711B2 (ja) 2007-02-09 2014-08-20 アクセルロン ファーマ， インコーポレイテッド 癌患者における骨成長を促進するためのアクチビン−ａｃｔｒｉｉａアンタゴニストおよびその使用
EP3243524A1 (en) 2007-09-18 2017-11-15 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
WO2010019261A1 (en) 2008-08-14 2010-02-18 Acceleron Pharma Inc. Use of gdf traps to increase red blood cell levels
EP2387412A4 (en) 2009-01-13 2013-04-03 Acceleron Pharma Inc PROCESS FOR INCREASING THE ADIPONECTIN MIRROR
US8178488B2 (en) 2009-06-08 2012-05-15 Acceleron Pharma, Inc. Methods for increasing thermogenic adipocytes
BRPI1010704B1 (pt) 2009-06-12 2021-12-14 Acceleron Pharma Inc Polipeptídeo recombinante, proteína de fusão recombinante, preparação farmacêutica e uso da mesma
AU2015203400A1 (en) * 2009-08-13 2015-07-16 Acceleron Pharma Inc. Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
CN105535938B (zh) * 2009-08-13 2022-04-26 阿塞勒隆制药公司 Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
JP6267425B2 (ja) 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用
AU2011326586A1 (en) 2010-11-08 2013-05-30 Acceleron Pharma, Inc. ActRIIA binding agents and uses thereof
GR1007832B (el) * 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
CN112933223A (zh) * 2012-10-24 2021-06-11 细胞基因公司 用于治疗贫血的方法
NZ707477A (en) * 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
EP2948161B1 (en) * 2013-01-25 2018-12-12 Shire Human Genetic Therapies, Inc. Follistatin in treating duchenne muscular dystrophy
BR112016024319B1 (pt) * 2014-04-18 2024-01-23 Acceleron Pharma Inc USO DE UMA COMPOSIÇÃO COMPREENDENDO UM ANTAGONISTA DE ActRII PARA A FABRICAÇÃO DE UM MEDICAMENTO PARA TRATAR OU PREVINIR UMA COMPLICAÇÃO DE ANEMIA FALCIFORME
EP3152237B1 (en) * 2014-06-04 2020-04-01 Acceleron Pharma Inc. Methods and compositions for treatment of disorders with follistatin polypeptides
AP2017009674A0 (en) * 2014-06-13 2017-01-31 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
EP3280727B1 (en) * 2015-04-06 2021-02-17 Acceleron Pharma Inc. Single-arm type i and type ii receptor fusion proteins and uses thereof
JP6959487B2 (ja) 2015-04-22 2021-11-02 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質
WO2017091706A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
WO2017177013A1 (en) * 2016-04-06 2017-10-12 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
RS65735B1 (sr) 2016-07-27 2024-08-30 Acceleron Pharma Inc Kompozicije za upotrebu u lečenju mijelofibroze
CN110036025B (zh) 2016-10-05 2024-03-22 阿塞勒隆制药公司 变体ActRIIB蛋白及其用途
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
WO2018089715A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
CA3082146A1 (en) 2017-11-09 2019-05-16 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
KR20200109330A (ko) 2018-01-12 2020-09-22 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법
CA3098679A1 (en) 2018-05-09 2019-11-14 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
WO2020100993A1 (ja) 2018-11-15 2020-05-22 三菱ケミカル株式会社 改変型アクチビンａ
CN114502190A (zh) * 2019-08-22 2022-05-13 加利福尼亚大学董事会 用于治疗天使综合征的ube3a
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
US20240368289A1 (en) * 2021-09-03 2024-11-07 Laekna Therapeutics Shanghai Co., Ltd. Anti-acvr2a antibodies and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1265208A (en) 1915-09-07 1918-05-07 Edward C Kahn Liquid-fuel burner.
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
AU8761391A (en) * 1990-09-13 1992-04-15 Children's Hospital Medical Center Of Northern California Method for increasing red blood cell production by treatment with activin or activin-related peptides
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
WO1996032503A1 (en) 1995-04-11 1996-10-17 The General Hospital Corporation Reverse two-hybrid systems
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
CA2302525A1 (en) 1997-08-29 1999-03-04 Human Genome Sciences, Inc. Follistatin-3
US6953662B2 (en) * 1997-08-29 2005-10-11 Human Genome Sciences, Inc. Follistatin-3
US6468543B1 (en) * 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
EP1356075A4 (en) 2000-10-16 2005-04-13 Compound Therapeutics Inc PROTEIN EQUIPMENT FOR ANTIBODY MIMETICS AND OTHER TIE PROTEINS
ATE472609T1 (de) 2001-04-26 2010-07-15 Amgen Mountain View Inc Kombinatorische bibliotheken von monomerdomänen
EP1390497A2 (en) * 2001-05-25 2004-02-25 Genset Human cdnas and proteins and uses thereof
US6855344B2 (en) * 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
US20070184052A1 (en) * 2003-05-09 2007-08-09 Lin Herbert Y Soluble tgf-b type III receptor fusion proteins
US20070135336A1 (en) 2003-09-15 2007-06-14 De Kretser David Follistatin isoforms and uses thereof
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
AU2005266875B2 (en) 2004-07-23 2012-07-26 Acceleron Pharma Inc. ActRII receptor polypeptides, methods and compositions
AU2005272646A1 (en) * 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
JP2008520207A (ja) 2004-11-16 2008-06-19 アヴィディア リサーチ インスティテュート タンパク質骨格およびその使用
CN105001320A (zh) 2005-11-23 2015-10-28 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
CA2652235A1 (en) * 2006-05-09 2007-11-22 Hemaquest Pharmaceuticals, Inc. Methods for treating blood disorders
CN101489704B (zh) * 2006-07-13 2011-04-20 巴斯夫欧洲公司 用于制备金属成型体的含粘合剂的热塑性组合物
NZ574331A (en) * 2006-07-21 2011-01-28 Lyne Lab Liquid compositions of calcium acetate
WO2008030367A2 (en) 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
US7547781B2 (en) * 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
AU2007334333B2 (en) * 2006-12-18 2013-05-30 Acceleron Pharma Inc. Activin-ActRII antagonists and uses for increasing red blood cell levels
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
JP5574711B2 (ja) 2007-02-09 2014-08-20 アクセルロン ファーマ， インコーポレイテッド 癌患者における骨成長を促進するためのアクチビン−ａｃｔｒｉｉａアンタゴニストおよびその使用
EP3243524A1 (en) * 2007-09-18 2017-11-15 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
DE102008016742B4 (de) * 2008-03-31 2010-01-14 Thyssenkrupp Presta Ag Lenksäule für ein Kraftfahrzeug

Also Published As

Publication number Publication date
NZ602471A (en) 2014-10-31
ES2852699T3 (es) 2021-09-14
WO2009158033A2 (en) 2009-12-30
KR20170038937A (ko) 2017-04-07
CA3049354A1 (en) 2009-12-30
EP2318028B1 (en) 2020-02-19
CN107252486A (zh) 2017-10-17
CA2729098C (en) 2018-02-13
EP2303917A4 (en) 2012-01-25
WO2009158015A2 (en) 2009-12-30
AU2009262968A1 (en) 2009-12-30
CA2729098A1 (en) 2009-12-30
EP2303917B1 (en) 2020-11-11
ES2791699T3 (es) 2020-11-05
KR102024444B1 (ko) 2019-09-23
NZ590326A (en) 2013-05-31
EP3804746A1 (en) 2021-04-14
CN107252486B (zh) 2021-10-22
JP2015187180A (ja) 2015-10-29
JP2022023184A (ja) 2022-02-07
KR20110031951A (ko) 2011-03-29
CN102131515A (zh) 2011-07-20
HK1245147A1 (zh) 2018-08-24
CA2729054A1 (en) 2009-12-30
JP2014088438A (ja) 2014-05-15
WO2009158033A3 (en) 2010-04-01
JP6643432B2 (ja) 2020-02-12
CN102131515B (zh) 2017-06-27
JP2011526626A (ja) 2011-10-13
EP3620795A1 (en) 2020-03-11
AU2016203098A1 (en) 2016-06-02
WO2009158015A3 (en) 2010-03-04
AU2020220046A1 (en) 2020-09-03
EP2318028A2 (en) 2011-05-11
JP5773868B2 (ja) 2015-09-02
EP2303917A2 (en) 2011-04-06
JP2017036331A (ja) 2017-02-16
JP2020041002A (ja) 2020-03-19
KR20190049912A (ko) 2019-05-09
EP2318028A4 (en) 2012-08-15
DK2318028T3 (da) 2020-05-04
AU2016203098B2 (en) 2018-03-08
AU2018204105A1 (en) 2018-06-28
JP2018184484A (ja) 2018-11-22
JP2019006805A (ja) 2019-01-17
KR20210047374A (ko) 2021-04-29

Similar Documents

Publication Publication Date Title
CA2729054C (en) Antagonists of actriib and uses for increasing red blood cell levels
US20200255495A1 (en) Antagonists of actriib and uses for increasing red blood cell levels
US20220118049A1 (en) Methods for dosing an actriib antagonist and monitoring of treated patients
US11168311B2 (en) Methods for treating anemia in a subject in need thereof
AU2010282361B2 (en) Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
AU2012326207A1 (en) Methods and compositions for treating ineffective erythropoiesis
HK40051596A (en) Antagonists of actriib and uses for increasing red blood cell levels
AU2021209153A1 (en) Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
AU2017204230A1 (en) Use of GDF traps to increase red blood cell levels
HK1156057A (en) Antagonists of actriib and uses for increasing red blood cell levels
HK1156057B (en) Antagonists of actriib and uses for increasing red blood cell levels

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140625